Last updated on November 2017

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations


Brief description of study

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Detailed Study Description

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway.

Clinical Study Identifier: TX11103

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Layne Jackson

Community Clinical Research Center
Anderson, IN USA
  Connect »